OBJECTIVE The study was designed to evaluate the efficacy of an ophthalmic formulation of 1% azithromycin in DuraSite((R)) (AzaSite, InSite Vision, Alameda CA, USA) and demonstrate equivalence with 0.3% tobramycin ophthalmic solution, USP, for the treatment of bacterial conjunctivitis as defined by the resolution of clinical signs and the eradication of pathogens. DESIGN Prospective, randomiz...

„Ocular drug delivery is one of the most interesting and challenging endeavours facing the pharmaceutical scientist...The anatomy, physiology and biochemistry of the eye render this organ exquisitely impervious to foreign substances...The challenge to the formulator is to outwit the protective barriers of the eye without causing permanent tissue damage...The ancient ophthalmic solutions, suspen...

AIM To compare the efficacy and safety of levofloxacin 0.5% ophthalmic solution (Quixin) with placebo for treatment of bacterial conjunctivitis. METHODS In this prospective, randomised, placebo controlled, double masked, multicentre study, 249 patients with bacterial conjunctivitis received either 0.5% levofloxacin (n = 126) or placebo (n = 123) for 5 days, administered every 2 hours on days ...

PURPOSE The purpose of this pilot study was to evaluate the safety and efficacy of azithromycin ophthalmic solution 1% in patients with contact lens-related dry eye (CLDE). METHODS This was a 4-week, single-center, open-label clinical trial in patients diagnosed with CLDE using the Contact Lens Dry Eye Questionnaire (CLDEQ). Fifty patients were enrolled in this study. The patients were random...

Background Ranibizumab (Lucentis) is an antibody fragment with high binding affinity for all isoforms of Vascular Endothelial Growth Factor A (VEGF-A) and is specifically developed for intraocular use. Since its introduction in 2007 it has been administered increasingly and in our hospital approximately 1650 intravitreal injections were given in 2013. Ranibizumab is injected monthly and in most...